Trazodone - Award Notice
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has awarded Golden State Medical Supply, Inc. (GSMS) a contract (SPE2D2-26-D-0013) for Trazodone tablets. This award, valued at an estimated $14,366,965.78 over 5 years, ensures the supply of this pharmaceutical product. The award date was July 22, 2026.
Scope of Work
This contract covers the supply of Trazodone tablets in various strengths and bottle counts. Specifically, it includes:
- Trazodone 50 MG Tablets in 90, 100, 500, and 1,000 count bottles.
- Trazodone 100 MG Tablets in 90, 100, 500, and 1,000 count bottles. Quantities specified in the contract are estimates only, indicating a requirements-type contract.
Contract & Timeline
- Contract Number: SPE2D2-26-D-0013
- Award/Effective Date: July 22, 2026
- Period of Performance: 5 years (estimated)
- Estimated Total Award Amount: $14,366,965.78
- Contract Type: Appears to be a requirements-type contract.
- Set-Aside: UNRESTRICTED
Evaluation
This award resulted from Solicitation SPE2D2-26-R-0003. Golden State Medical Supply, Inc.'s Final Proposal Revision (FPR), submitted on April 1, 2026, was accepted as the lowest price technically acceptable offer. The original solicitation involved amendments to extend the closing date.
Additional Notes
The contract incorporates extensive Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses. Appendix A of the award document lists current Pharmaceutical Prime Vendors, including Amerisource Bergen Drug Co., Cardinal Health, DMS Pharmaceutical Group Inc., and McKesson Corp.